Successful treatment of a prolactin-producing pituitary macroadenoma with intravaginal bromocriptine mesylate: A novel approach to intolerance of oral therapy

Eugene Katz, Horst F. Schran, Eli Y. Adashi

Research output: Contribution to journalArticle

Abstract

A 37-year-old woman with a symptomatic 18-mm prolactinsecreting pituitary adenoma could not be managed with oral bromocriptine mesylate because of unacceptable gastrointestinal side effects. However, when given the medication intravaginally, the patient was successfully treated as assessed by evident tumor shrinkage and diminished secretory activity. Serum bromocriptine levels were approximately six to eight times higher than those reported after oral administration. The vaginal route may help reduce some of the adverse effects of bromocriptine mesylate experienced during oral administration and may possibly allow lowering of the overall effective dose by avoiding first liver passage.

Original languageEnglish (US)
Pages (from-to)517-520
Number of pages4
JournalObstetrics and Gynecology
Volume73
Issue number3
StatePublished - 1989
Externally publishedYes

Fingerprint

Bromocriptine
Prolactin
Oral Administration
Pituitary Neoplasms
Therapeutics
Liver
Serum
Neoplasms

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Successful treatment of a prolactin-producing pituitary macroadenoma with intravaginal bromocriptine mesylate : A novel approach to intolerance of oral therapy. / Katz, Eugene; Schran, Horst F.; Adashi, Eli Y.

In: Obstetrics and Gynecology, Vol. 73, No. 3, 1989, p. 517-520.

Research output: Contribution to journalArticle

@article{2acaf1cdffd94156baa261b589d34447,
title = "Successful treatment of a prolactin-producing pituitary macroadenoma with intravaginal bromocriptine mesylate: A novel approach to intolerance of oral therapy",
abstract = "A 37-year-old woman with a symptomatic 18-mm prolactinsecreting pituitary adenoma could not be managed with oral bromocriptine mesylate because of unacceptable gastrointestinal side effects. However, when given the medication intravaginally, the patient was successfully treated as assessed by evident tumor shrinkage and diminished secretory activity. Serum bromocriptine levels were approximately six to eight times higher than those reported after oral administration. The vaginal route may help reduce some of the adverse effects of bromocriptine mesylate experienced during oral administration and may possibly allow lowering of the overall effective dose by avoiding first liver passage.",
author = "Eugene Katz and Schran, {Horst F.} and Adashi, {Eli Y.}",
year = "1989",
language = "English (US)",
volume = "73",
pages = "517--520",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Successful treatment of a prolactin-producing pituitary macroadenoma with intravaginal bromocriptine mesylate

T2 - A novel approach to intolerance of oral therapy

AU - Katz, Eugene

AU - Schran, Horst F.

AU - Adashi, Eli Y.

PY - 1989

Y1 - 1989

N2 - A 37-year-old woman with a symptomatic 18-mm prolactinsecreting pituitary adenoma could not be managed with oral bromocriptine mesylate because of unacceptable gastrointestinal side effects. However, when given the medication intravaginally, the patient was successfully treated as assessed by evident tumor shrinkage and diminished secretory activity. Serum bromocriptine levels were approximately six to eight times higher than those reported after oral administration. The vaginal route may help reduce some of the adverse effects of bromocriptine mesylate experienced during oral administration and may possibly allow lowering of the overall effective dose by avoiding first liver passage.

AB - A 37-year-old woman with a symptomatic 18-mm prolactinsecreting pituitary adenoma could not be managed with oral bromocriptine mesylate because of unacceptable gastrointestinal side effects. However, when given the medication intravaginally, the patient was successfully treated as assessed by evident tumor shrinkage and diminished secretory activity. Serum bromocriptine levels were approximately six to eight times higher than those reported after oral administration. The vaginal route may help reduce some of the adverse effects of bromocriptine mesylate experienced during oral administration and may possibly allow lowering of the overall effective dose by avoiding first liver passage.

UR - http://www.scopus.com/inward/record.url?scp=0024535223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024535223&partnerID=8YFLogxK

M3 - Article

C2 - 2915884

AN - SCOPUS:0024535223

VL - 73

SP - 517

EP - 520

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 3

ER -